RxDoctor Payments Data

Magen Nessi, NP

Family · Woodstock, GANPI 1821434572

Payments from drug & device makers

$13,435in general payments, 2019–2025

Across 318 payments — averaging $42.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$3K
  • Teleflex LLC$2K
  • Telix Pharmaceuticals$1K
  • Sumitomo Pharma America, Inc.$962
  • Johnson & Johnson$915
  • Astellas Pharma US Inc$528
  • plus $6K from 36 others

What the payments were for

  • Speaking & faculty fees$1431%
  • Travel & lodging$2,55319%
  • Food & beverage$10,43278%
  • Education$3082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,435 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$193,313
Medicare patients
763
Services billed
13,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide26$375,877
XtandiEnzalutamide12$158,754
GemtesaVibegron147$101,566
OrgovyxRelugolix23$60,116
MyrbetriqMirabegron68$58,880
Methenamine Hippurate123$8,938
Testosterone22$7,151
Estradiol69$4,871
Tamsulosin Hcl304$4,583
Testosterone Cypionate64$3,006
Trospium Chloride31$2,076
Finasteride92$1,156
Dutasteride24$1,067
Solifenacin Succinate28$1,006
Oxybutynin Chloride ErOxybutynin Chloride34$881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$915$375,87726 claims
Astellas Pharma US IncXtandi, Myrbetriq$528$217,63580 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$962$161,682170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Woodstock

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →